A major long-term study led by researchers at Cedars-Sinai Health Sciences University is raising new safety concerns about commonly used irritable bowel syndrome treatments. The research, published in Communications Medicine, tracked more than 650,000 adults in the United States with IBS over nearly 20 years using electronic health record data, making it the largest real-world analysis to date focused on the long-term safety of IBS treatments.
Medication Risks Identified
The study examined patients taking a range of treatments including FDA-approved IBS medications, antidepressants, antispasmodics, and opioid-based antidiarrheal drugs such as loperamide and diphenoxylate. Long-term antidepressant use was associated with a 35% higher risk of death. Use of loperamide and diphenoxylate was linked to roughly double the risk of death compared with those not using these medications. Other commonly recommended treatments, including FDA-approved medications and antispasmodics, were not associated with an increased risk of death.
According to Ali Rezaie, medical director of the GI Motility Program at Cedars-Sinai and senior author of the study, “Many patients are diagnosed with IBS at a young age and may remain on medications for years. However, most clinical trials of these medications last less than a year, so we know very little about their long-term safety.”
Important Caveats
The study does not prove that these medications directly cause death; the observed links may reflect a greater likelihood of serious health complications among those taking them, including cardiovascular events, falls, and stroke. Researchers emphasized that while the increased risk is statistically meaningful, the overall risk for any single patient remains low. “IBS patients should not panic, but they do need to understand and weigh the small but meaningful risks when considering long-term treatments,” said Rezaie. Patients should speak with their healthcare provider about the safest and most effective options for managing their symptoms.
Rezaie noted that further studies are needed to confirm these findings and determine which patients may face the greatest risk, and that future treatment guidelines should place more emphasis on the long-term safety of medications used to manage IBS.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://scitechdaily.com/millions-take-these-ibs-drugs-but-a-new-study-finds-serious-risks/